Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Swift Treatment of Stage I Melanoma Aided Survival

J Am Acad Dermatol; ePub 2017 Oct 17; Conic, et al

Expeditious treatment of stage I melanoma is associated with improved outcomes, according to a recent study. Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (n=153,218). The t test and chi-square test were used to compare variables; Cox regression was used for multivariate analysis. Researchers found:

  • In a multivariate analysis, patients in all stages who were treated between 90 and 119 days after biopsy and >119 days had a higher risk for mortality compared with those treated within 30 days of biopsy.
  • In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days, 60 to 89 days, 90 to 119 days, and >119 days after biopsy.
  • Surgical timing did not affect survival in stages II and III.


Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. [Published online ahead of print October 17, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.08.039.